CJC-1295 (without DAC) vs HCG
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both CJC-1295 (without DAC) and HCG can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 (without DAC) HCG
Weight 3,367.97 Da 36,700 Da
Half-life 30 minutes - 2 hours 24-36 hours
Chain 30 amino acids 237 amino acids (alpha: 92, beta: 145)
Type GHRH analog Heterodimeric glycoprotein
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
HCG
01 Maintains testicular function during TRT
02 Preserves fertility and prevents testicular atrophy
03 Stimulates endogenous testosterone production
04 Induces ovulation in women
05 FDA-approved for multiple indications
06 Well-established safety profile
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
HCG
250-1500 IU (lower for TRT adjunct, higher for fertility) / 2-3 times weekly, or every other day for lower doses
TRT Adjunct (Low) 250-500 IU Every other day
TRT Adjunct (Standard) 500-1000 IU Twice weekly
HCG Monotherapy 1500-2000 IU 2-3x weekly
Fertility (with FSH) 1500-2000 IU 2-3x weekly
Cryptorchidism (Pediatric) 1000-5000 IU 2-3x weekly for 3-4 weeks
Ovulation Trigger (Female) 5000-10,000 IU Single dose
PCT Protocol 1000-1500 IU Every other day for 2-3 weeks
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
HCG
Gynecomastia (breast tenderness/swelling) due to increased estrogen
Headaches, irritability, and mood swings (especially initially)
Fluid retention and edema
Potential antibody formation with long-term use
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Hormone-sensitive cancers (prostate, breast)
Pregnancy (except as prescribed)
Precocious puberty risk in children
Research Evidence
CJC-1295 (without DAC) HCG
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 2024
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.